The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Market Overview: Strong Growth in 2024

• 2023 Market Size: $4.07 billion.
• 2024 Projection: Expected to grow to $4.29 billion.
• Growth Rate: 5.3% CAGR.
• Key Drivers:
  • Rising cases of Helicobacter pylori infections.
  • Increased use of nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Growing geriatric population.
  • Heightened awareness of gastric ulcer prevention.
  • Increasing stress-related disorders.

Looking Ahead: Market Growth Forecast

• 2028 Market Size: Projected to reach $5.34 billion.
• Forecasted Growth Rate: 5.6% CAGR.
• Growth Factors:
  • Improved diagnostic techniques.
  • Unhealthy dietary habits.
  • Advances in treatment options, including proton pump inhibitors (PPIs).
  • Aging population increasing disease burden.
  • Expansion of healthcare infrastructure, particularly in emerging markets.
• Major Trends:
  • Shift towards combination therapies.
  • Increased preference for minimally invasive procedures.
  • Integration of digital health solutions.
  • Rising demand for over-the-counter (OTC) medications.
  • Expansion of personalized medicine approaches.

Read More On The Gastric Ulcers Market Report 2024 – https://www.thebusinessresearchcompany.com/report/gastric-ulcers-global-market-report

Key Market Driver: Aging Population

• Geriatric Population Growth: A significant driver of market expansion.
  • Impact: Increased vulnerability to gastric ulcers due to:
    • Higher NSAID usage.
    • Reduced mucosal protection in the elderly.
• Global Aging Trends:
  • The population aged 60+ will rise from 1 billion in 2020 to 1.4 billion by 2030.
  • By 2050, individuals aged 80+ are expected to triple, reaching 426 million.
  • This demographic shift underlines the growing demand for effective ulcer treatments.

Major Players in the Global Gastric Ulcers Market

• Leading Companies:
  • Pfizer Inc.
  • Merck & Co Inc.
  • AbbVie Inc.
  • Sanofi S.A.
  • AstraZeneca plc.
  • Abbott Laboratories.
  • Novartis AG.
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Co. Ltd.
  • Amgen Inc.
• Emerging Competitors:
  • Viatris Inc.
  • Daiichi Sankyo Company Limited.
  • Eisai Co. Ltd.
  • Cadila Pharmaceuticals.

Market Trends: The Rise of Generic Capsules

• Focus on Innovation:
  • Companies are prioritizing the development of generic capsule medications.
• Example: Dr. Reddy’s Laboratories launched a generic version of Librax in 2021.
  • Benefits: More affordable options for patients, expanding access to treatment.
  • Impact: Strengthening the range of available ulcer treatment options.

Mergers and Acquisitions: Expanding Market Reach

• Notable Partnership:
  • Dr. Reddy’s Laboratories & HK Inno.N. Corporation (2022).
  • Objective: To commercialize Tegoprazan, a novel gastrointestinal treatment, in India and emerging markets.
  • Role Distribution:
    • HK Inno.N.: Responsible for manufacturing and supply.
    • Dr. Reddy’s: Handles clinical development, registration, and sales.

Regional Insights: A Global Perspective

• Current Leader: North America was the largest market region in 2023.
• Fastest Growth: Asia-Pacific is expected to lead in growth during the forecast period, driven by expanding healthcare infrastructure and rising awareness of gastric ulcer treatment.

Conclusion
The global gastric ulcers market is on a robust growth trajectory, driven by demographic shifts, advancements in treatment, and evolving healthcare infrastructure. With major players investing in innovation and emerging markets, the market is poised for significant expansion, particularly in regions like Asia-Pacific. The increasing geriatric population and the rise of generic capsules are likely to shape the market landscape in the coming years.

Request for A Sample Of The Global Gastric Ulcers Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=17160&type=smp